Skip to content
10-Q

Quarterly Report

ARCUTIS BIOTHERAPEUTICS, INC. ARQT

0001787306-25-000092

← back to feed
Filed
May 6, 2025 12:00 AM ET
Period of report

On SEC.gov

Financials in this filing

Metric Period Value
Shares Outstanding Q1 2025 · May 1, 2025 119.2M sh
Long Term Debt Q1 2025 · Mar 31, 2025 $107.62M
Long Term Debt Q1 2025 · Dec 31, 2024 $107.2M
Cash And Equivalents Q1 2025 · Mar 31, 2025 $53.1M
Cash And Equivalents Q1 2025 · Dec 31, 2024 $71.34M
Current Liabilities Q1 2025 · Mar 31, 2025 $91.13M
Current Liabilities Q1 2025 · Dec 31, 2024 $81.01M
Total Liabilities Q1 2025 · Mar 31, 2025 $201.45M
Total Liabilities Q1 2025 · Dec 31, 2024 $191.35M
Current Assets Q1 2025 · Mar 31, 2025 $323.67M
Current Assets Q1 2025 · Dec 31, 2024 $335.82M
Total Assets Q1 2025 · Mar 31, 2025 $344.11M
Total Assets Q1 2025 · Dec 31, 2024 $348.89M
Shares Diluted Q1 2025 · Mar 31, 2024 111.05M sh
Capex Q1 2025 · Mar 31, 2024 $0
Operating Cash Flow Q1 2025 · Mar 31, 2024 −$31.6M
Stockholders Equity Q1 2025 · Mar 31, 2024 $224.94M
Stockholders Equity Q1 2025 · Dec 31, 2023 $88.67M
Eps Diluted Q1 2025 · Mar 31, 2024 −$0.32
Eps Basic Q1 2025 · Mar 31, 2024 −$0.32
Sga Expense Q1 2025 · Mar 31, 2024 $54.79M
Rd Expense Q1 2025 · Mar 31, 2024 $23.14M
Net Income Q1 2025 · Mar 31, 2024 −$35.38M
Operating Income Q1 2025 · Mar 31, 2024 −$31.62M
Cost Of Revenue Q1 2025 · Mar 31, 2024 $3.26M
Revenue Q1 2025 · Mar 31, 2024 $49.57M